Antibody Response to COVID-19 Virus - Heilongjiang Province and Gansu Province, China, 2020.

Mao, Naiying; Zhu, Zhen; Zhu, Shuangli; Yu, Deshan; Xu, Jun; Cui, Aili; Cao, Lei; Guo, Jinyuan; Wang, Huiling; Wang, Dongyan; Yan, Dongmei; Song, Yang; Yang, Qian; Jiang, Zhongyi; Zhang, Hui; Shu, Chang; Yang, Ming; Wang, Yanhai; Xiao, Jinbo; Han, Zhenzhi; Zhang, Yong; Zhang, Yan; Xu, Wenbo

Mao, Naiying; Zhu, Zhen; Zhu, Shuangli; Yu, Deshan; Xu, Jun; Cui, Aili; Cao, Lei; Guo, Jinyuan; Wang, Huiling; Wang, Dongyan; Yan, Dongmei; Song, Yang; Yang, Qian; Jiang, Zhongyi; Zhang, Hui; Shu, Chang; Yang, Ming; Wang, Yanhai; Xiao, Jinbo; Han, Zhenzhi; Zhang, Yong; Zhang, Yan; Xu, Wenbo.

Mao N; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Zhu Z; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Zhu S; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Yu D; Gansu Provincial Center for Disease Control and Prevention, Lanzhou, Gansu, China.
Xu J; Heilongjiang Provincial Center for Disease Control and Prevention, Haerbin, Heilongjiang, China.
Cui A; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Cao L; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Guo J; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Wang H; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Wang D; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Yan D; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Song Y; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Yang Q; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Jiang Z; Gansu Provincial Center for Disease Control and Prevention, Lanzhou, Gansu, China.
Zhang H; Gansu Provincial Center for Disease Control and Prevention, Lanzhou, Gansu, China.
Shu C; Heilongjiang Provincial Center for Disease Control and Prevention, Haerbin, Heilongjiang, China.
Yang M; Heilongjiang Provincial Center for Disease Control and Prevention, Haerbin, Heilongjiang, China.
Wang Y; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Xiao J; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Han Z; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Zhang Y; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Zhang Y; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.
Xu W; NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; Beijing, China.

China CDC Wkly ; 2(34): 645-650, 2020 Aug 21.

Article in English | MEDLINE | ID: covidwho-1355404

ABSTRACT

ABSTRACT

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Coronavirus disease 2019 (COVID-19) has become a global pandemic, while the profile of antibody response against the COVID-19 virus has not been well clarified. WHAT IS ADDED BY THIS REPORT? In this study, 210 serum samples from 160 confirmed COVID-19 cases with different disease severities were recruited. The IgM, IgA, IgG, and neutralizing antibodies (NAb) against COVID-19 virus were determined. Our findings indicated that four antibodies could be detectable at low levels within 2 weeks of disease onset, then rapidly increasing and peaking from the 3rd to 5th Weeks. NAb decreased between 5th and 9th Weeks, and a higher IgM/IgA level was observed in the groups with mild/moderate severity within 2 weeks (p<0.05), while all 4 types of antibodies were higher in the group with severe/critical severity after 4 weeks (p<0.05). WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Our study on the dynamics of serological antibody responses against COVID-19 virus among COVID-19 patients complements the recognition regarding the humoral immune response to COVID-19 virus infection. The findings will help in the interpretation of antibody detection results for COVID-19 patients and be beneficial for the evaluation of vaccination effects.

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: China CDC Wkly Year: 2020 Document Type: Article Affiliation country: Ccdcw2020.180

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google